Peptide YY3-36 intranasal - Adhera Therapeutics
Alternative Names: Peptide YY3-36 intranasal; Peptide YY3-36 nasal spray; PYY3-36 intranasal; PYY3-36 nasal sprayLatest Information Update: 17 Apr 2019
At a glance
- Originator Thiakis
- Developer Marina Biotech
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Neuropeptide Y2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity